Media

Francois Martelet, chief executive of NetScientific PLC (LON:NSCI) caught up with Proactive’s Andrew Scott to update on developments within the IP commercialisation specialist’s portfolio. Francois Martelet, chief executive of NetScientific PLC (LON:NSCI), caught up with Proactive’s Andrew Scott to update on developments within the IP commercialisation specialist’s portfolio. ”All of our companies are game-changing and unique in their sectors”, Martelet says. Most recently NetScientific …

London, UK – 05 January 2018 – NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, today announces that its management team will attend the following key investor and partnering conferences in the first half of 2018: IDATE DigiWorld – London Members Yearly Meeting January 18th 2018 London, UK Francois Martelet, CEO, to attend   BAB TAG Networking Event January 24th 2018 London, UK …

  London, UK – 08 December 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group announces that Francois Martelet, Chief Executive Officer, will be presenting at the Shares Investor Evening in London at the Novotel Tower Bridge, London EC3N 2NR on Thursday 14 December at 19:30 GMT # # # For more information, please contact: NetScientific François R. Martelet, M.D., …

François Martelet M.D Netscientific Chief Executive Officer speaks about Netscientific transatlantic healthcare technology group. NetScientific is a transatlantic healthcare IP commercialisation group. We fund and develop companies that significantly improve the health and well-being of people with chronic diseases. Through our US-UK network, we source, develop and manage early/mid-stage healthcare technology companies focused on Diagnostics, Digital health and Therapeutics. We are focused on …

NetScientific plc (LON:NSCI) chief executive and chairman Francois Martelet hailed recent news from portfolio company Vortex Biosciences as a “very important” milestone. Vortex has been awarded a CE Mark for its circulating tumour cell (CTC) capture system and has registered a Class I medical device with the US FDA (Food and Drug Administration). It means moving the selling of the VTX-1 Liquid Biopsy …